[Cytostatic treatment of prostatic carcinoma. Evaluation study of estramustinphosphate].
D000368:Aged; D002219:Carbamates / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use; D004967:Estrogens / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D005069:Evaluation Studies as Topic; D006801:Humans; D008297:Male; D008875:Middle Aged; D009588:Nitrogen Mustard Compounds / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D010756:Phosphoric Acids / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use; D011471:Prostatic Neoplasms / Q000188:drug therapy*; D013997:Time Factors
D002219:Carbamates; D004967:Estrogens; D009588:Nitrogen Mustard Compounds; D010756:Phosphoric Acids
Die zytostatische Therapie des Prostatakarzinoms. Studie über Estramustinphosphat.